Foley & Lardner LLP, an international law firm, released a white paper analysis, which discusses the legal authority and statutory obligation of the Drug Enforcement Administration (DEA) to promulgate regulations specifying the circumstances in which a special registration may be issued, and more.Notably, it concludes:“The recently released proposed rule does not satisfy DEA’s obligation as [...]
Telemedicine prescribing of controlled substances when the practitioner and the patient have not had a prior in-person medical evaluation (RIN: 1117-AB40)Drug Enforcement Administration Notice of Proposed RulemakingPublic comments due March 31, 2023DEA Resources: Rule Text Highlights for Medical PractitionersDEA Summary ChartSee companion buprenorphine rule summary hereProposed Rule OverviewThe Ryan Haight Act of 2008 directed the [...]
The Drug Enforcement Administration (DEA) released its Notice of Proposed Rulemaking (NPRM) on buprenorphine via telemedicine encounter, a summary, and highlights for medical practitioners. The proposed rule amends the DEA’s regulations, in concert with the Department of Health and Human Services (HHS), on the circumstances under which individual practitioners are authorized to prescribe schedule [...]